We surveyed panel members about the FDA advisory on Provention Bio’s teplizumab to delay type 1 diabetes—discover their top concerns and expected impact.
dQ&A reveals how Walmart’s CareZone deal, low mail-order NPS scores, and a pandemic push toward home delivery are reshaping pharmacy apps for diabetes.
Our latest work highlights how menopause alters insulin sensitivity and diabetes management, yet the intersection remains under-researched. This study explores how menopause stages impact diabetes outcomes.
